LA JOLLA, Calif., April 8, 2019 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs, today announced that it will present
preclinical data on the therapeutic potential of its lead anti-miR
for the treatment of nonalcoholic steatohepatitis (NASH), at
the EASL International Liver Congress™ 2019 being
held April 10-14, 2019 in Vienna, Austria.
"We are pleased to be presenting preclinical data during this
year's EASL International Liver Congress that we believe
demonstrates the potential of our lead anti-miR-132 to be a
promising therapeutic for the treatment of NASH," said Jay Hagan, President and Chief Executive Officer
of Regulus.
Details of the late breaker poster presentation are as follows
and will be available for download at the time of presentation at
http://regulusrx.com/publications.
Poster Board #LBP-40
Title: "Development of Oligonucleotide-Based miR-132
Antagonists for the Treatment of NASH", Papazyan, R., et
al.
Session: Late Breaker Poster session, NAFLD
therapy
Poster display date and time: April
11-13, 9:00-18:30
- Demonstration of miR-132 upregulation (2 to 4-fold) in liver
tissues of NASH patients compared to those of healthy donors.
- Demonstration of efficacy in preclinical models of NASH with
the Company's lead anti-miR-132. Results showed reduced liver
triglyceride levels by up to 50%, neutralized serum liver enzyme
levels (ALT and AST), enhanced glucose tolerance, and improved
histopathological scores. Therapeutic effects were sustained for up
to 6 weeks following the final dose.
- Global gene expression profiling revealed significant increase
in metabolic genes and a decrease in inflammatory and fibrotic
genes.
About NASH
Nonalcoholic steatohepatitis (NASH) is an inflammatory liver
disease associated with excessive fat accumulation in the liver
which can lead to progressive fibrosis. The prevalence of
NASH in the United States is
thought to be 3-5% of the general population, with a sizable
proportion of the patients having either severe disease or high
risk of progression to cirrhosis, liver cancer or liver
failure.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate
headquarters in La Jolla,
CA. For more information, please visit
http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected ability
of Regulus to undertake certain activities and accomplish certain
goals and objectives (including with respect to development and
other activities related to its miR-132 program in NASH).
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will,"
"goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. These and other risks
concerning Regulus' financial position and programs are described
in additional detail in Regulus filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-to-present-preclinical-efficacy-data-highlighting-potential-of-novel-treatment-for-nonalcoholic-steatohepatitis-at-the-international-liver-congress-2019-300825712.html
SOURCE Regulus Therapeutics Inc.